Patient characteristics
| Patient characteristic | Outcome |
|---|---|
| Sex [n (%)] | |
| Male | 34 (59) |
| Female | 24 (41) |
| Age at diagnosis (year) | 60 |
| Race [n (%)] | |
| Caucasian | 50 (86) |
| Black | 7 (12) |
| Primary tumor site [n (%)] | |
| Appendix | 2 (3) |
| Colon | 3 (5) |
| Lung | 1 (2) |
| Pancreas | 14 (24) |
| Rectosigmoid | 1 (2) |
| Rectum | 2 (3) |
| Small bowel | 24 (41) |
| Unknown site | 11 (19) |
| Liver metastasis [n (%)] | |
| Present | 49 (84) |
| Absent | 9 (16) |
| Grade* [n (%)] | |
| 1 | 21 (38) |
| 2 | 25 (45) |
| 3 | 4 (7) |
| Differentiation** [n (%)] | |
| Well | 47 (90) |
| Moderate | 2 (4) |
| Poor | 1 (2) |
| Eastern Cooperative Oncology Group (ECOG) score at first treatment | 0.58 |
| Prior treatment [n] | |
| Octreotide | 47 |
| Lanreotide | 3 |
| Everolimus | 8 |
| Denosumab | 3 |
*: tumor gradings are defined as 1 = mitotic rate < 2 mitosis/2 mm2 and Ki67 index < 3%; 2 = mitotic rate 2–20 mitosis/2 mm2 and Ki67 index 3–20%; 3 = mitotic rate > 20 mitosis/2 mm2 and Ki67 index > 20% [14]; **: well-differentiated tumors demonstrated low mitotic rate and low-grade bland histology. Moderate-differentiated tumors demonstrated moderate mitotic rate and moderate-grade histology. Poorly differentiated neuroendocrine carcinoma demonstrated a high-mitotic rate and high-grade histology similar in appearance to small cell carcinomas [15]
